BlogHotel.orgAccueil | Créer un blog | Imprimer la page Imprimer | Blog hasard Au hasard | Chercher des blogs Rechercher | Entrer dans le chat du blog Chat | | Jeux Jeux | Adminitration et édition du Blog Manager

freemexy Accueil | Profil | Archives | Amis
freemexy

Low-Dose Tamoxifen powder May Be an Option to Reduce Risk of Recurrence8/11/2019
A study found that a daily, low dose of tamoxifen after surgery reduced the risk of recurrence (the disease coming back), as well as the risk of new invasive breast cancer, in women diagnosed with hormone-receptor-positive breast intraepithelial neoplasia, which is non-invasive breast disease.wisepoqder Tamoxifen powder

The research was presented on Dec. 6, 2018, at the San Antonio Breast Cancer Symposium. Read the abstract of “A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ.”

Watch Marisa Weiss, M.D., chief medical officer of Breastcancer.org, discuss the TAM-01 study and what the findings mean for you.
Breast intraepithelial neoplasia refers to a group of non-invasive conditions where abnormal cells are found in specific areas of the breast. A neoplasia is a collection of abnormal cells. Intraepithelial cells are cells that form the surface or lining of an organ, such as the breast ducts or lobules (the milk-producing gland at the end of the ducts). Non-invasive means the abnormal cells haven’t spread from the milk ducts or lobules into any healthy surrounding breast tissue.

Ductal carcinoma in situ (DCIS)
When the abnormal cells are in the milk ducts, the growth is called ductal carcinoma in situ (DCIS). DCIS isn’t life-threatening, but having DCIS can increase the risk of developing an invasive breast cancer later on. When you have had DCIS, you are at higher risk for the DCIS coming back or for developing a new, invasive breast cancer compared to a person who has never had DCIS.

Atypical ductal hyperplasia (ADH)
With atypical ductal hyperplasia (ADH), there are more cells than usual in the lining of the breast duct. The cells are abnormal, but not as abnormal as they would be in a diagnosis of DCIS. ADH is considered a benign breast condition that is linked to a moderate increase in the risk of invasive breast cancer.

Lobular carcinoma in situ (LCIS)
When the abnormal cells are in the lobules, the growth is called lobular carcinoma in situ (LCIS). LCIS is much less common than DCIS. Despite the fact that its name includes the term “carcinoma,” LCIS is not a true breast cancer. Rather, LCIS is an indication that a person is at higher-than-average risk for developing invasive breast cancer at some point in the future.

0 Commentaires | poster un commentaire | Lien Permanent

Lower-Dose Tamoxifen powder Works As Well As High-Dose8/11/2019
Tamoxifen is considered a vital weapon in the fight against breast cancer, but many women who have to take the drug struggle with its significant side effects.

Now, new research shows that a lower dose of the hormone therapy helped prevent breast cancer from returning and guarded against new cancers in women who had high-risk breast tissue.On top of that, the lower dose -- just 5 milligrams daily -- came with fewer troubling side effects.wisepoqder β-agonist Powder

"Low-dose tamoxifen is as effective as the standard dose," said study author Dr. Andrea De Censi. He is director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera -- S.C. Oncologia Medica in Genoa, Italy.De Censi said the rate of side effects -- such as hot flashes, vaginal dryness, pain during intercourse and muscle pain -- was similar to the rate that occurred with a placebo pill. The side effect rate for the low-dose therapy was significantly less than what previous research has shown with the standard 20 milligram (mg) dose of tamoxifen, he noted.

In addition, the risk of serious side effects, such as blood clots and endometrial cancer, were similar to that of the placebo, and less than what typically occurs with the 20 mg dose, De Censi said.Hormone therapy for breast cancer interferes with the growth of cancer cells in a few ways. One is by blocking the body from producing certain hormones. Another is by disrupting the effects of certain hormones on cancer cells, according to the American Cancer Society.

In the case of tamoxifen, it works by binding to estrogen-receptors. Some cancers -- those called estrogen-receptor positive -- are fueled by estrogen. Tamoxifen blocks the estrogen-receptors on cancer cells, keeping them from getting the fuel they need to grow.De Censi said he was interested in doing the study because the minimum effective dose of tamoxifen hadn't been researched.

The drug was developed in the late 1960s, he said, and at the time researchers weren't looking for the minimum effective dose because prevention was the key issue. However, above a certain dose, tamoxifen won't produce any extra benefit, but it will raise the risk of side effects, De Censi said.

0 Commentaires | poster un commentaire | Lien Permanent

Page 200 of 834
Précédent | Suivant